3.9 Article

The functional MICA-129 polymorphism is associated with skin but not joint manifestations of psoriatic disease independently of HLA-B and HLA-C

Journal

TISSUE ANTIGENS
Volume 82, Issue 1, Pages 43-47

Publisher

WILEY-BLACKWELL
DOI: 10.1111/tan.12126

Keywords

HLA-B; HLA-C; major histocompatibility complex class I chain-related gene A; MICA-129; psoriasis; psoriatic arthritis

Funding

  1. Krembil Foundation
  2. Canadian Institutes of Health Research (CIHR)
  3. University Health Network
  4. Abbott Psoriatic Arthritis Fellowship
  5. Canadian Arthritis Network
  6. MRC [U105261167, G0902100]
  7. British Heart Foundation [RG/08/014/24067] Funding Source: researchfish
  8. Medical Research Council [MC_U105261167, MR/L501566/1, MR/L003120/1, MC_EX_G0902100] Funding Source: researchfish
  9. National Institute for Health Research [NF-SI-0512-10165] Funding Source: researchfish
  10. MRC [MC_EX_G0902100, MC_U105261167, MR/L003120/1] Funding Source: UKRI

Ask authors/readers for more resources

A methionine/valine polymorphism at amino acid 129 of the major histocompatibility complex class I chain-related gene A (MICA-129) categorizes alleles into strong and weak binders of the natural killer (NK) and T-cell receptor NKG2D. We investigated whether MICA-129 is differentially associated with skin and joint manifestations of psoriatic disease (PsD) independently of human leukocyte antigen (HLA)-C and HLA-B in patients and controls from Toronto and St. John's. The MICA-129 methionine (Met) allele, particularly Met/Met homozygosity, was strongly associated with both cutaneous psoriasis (PsC) and psoriatic arthritis (PsA) independently of HLA-B and HLA-C in Toronto patients, and was also associated with PsA in St. John's patients, but with no additional effect of Met/Met homozygosity. No association remained after adjustment for HLA alleles in St. John's patients. MICA-129 was not associated with PsA when compared with PsC. We conclude that MICA-129 is a marker of skin manifestations of PsD that is independent of HLA class I in Toronto patients.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

3.9
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available